Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies

American Journal of Health-System Pharmacy

Volumn 66, Issue 12 SUPPL. 4, 2009, Pages

  Owens Jr , Robert C ^a   Shorr, Andrew F ^b  

^a MAINE MEDICAL CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Aminoglycosides; Antibiotics; Antiinfective agents; Community acquired infections; Dosage; Macrolides; Methodology; Minimum inhibitory concentration; Pharmacokinetics; Pneumonia; Quinolones; Rational therapy; Resistance

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFEPIME; CEFOTAXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; ERTAPENEM; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; HUMAN; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SEPSIS; STREPTOCOCCUS PNEUMONIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; TIME;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; TIME FACTORS;

EID: 68849107631     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/090087d     Document Type: Conference Paper

References (49)

1. Doern GV, Heilmann KP, Huynh HK et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-9.
2. Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006; 4:36-45.
3. Grundmann H, Aires-de-Sousa M, Boyce J et al. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006; 368:874-85.
4. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis. 2005; 11:802-7.
5. Jacobs MR. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 2007; 30 (suppl 2):S122-6.
6. Suzuki S, Yamazaki T, Narita M et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006; 50:709-12.
7. Melo-Cristino J, Santos L, Ramirez M. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004. Rev Port Pneumol. 2006; 12:9-30.
8. Aloush V, Navon-Venezia S, Seigman-Igra Y et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006; 50:43-8.
9. Herwaldt LA, Cullen JJ, Scholz D et al. A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. Infect Control Hosp Epidemiol. 2006; 27:1291-8.
10. Klevens RM, Edwards JR, Richards CL Jr et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007; 122:160-6.
11. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ. 2006; 333:281.
12. Levy SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother. 2002; 49:25-30.
13. Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004; 38:1279-86.
14. Calbo E, Garau J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. Respiration. 2005; 72:561-71.
15. Goldberg J, Owens RC Jr. Optimizing antimicrobial dosing in the critically ill patient. Curr Opin Crit Care. 2002; 8:435-40.
16. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003; 17:529-43.
17. Ambrose PG. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design. Clin Infect Dis. 2008; 47 (suppl 3):S225-31.
18. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007; 44:79-86.
19. Rapp RP. Principles of treatment of CAP - part 2: implications of antimicrobial pharmacokinetics/pharmacodynamics. Pharm Times. 2007; 79-88.
20. Centers for Medicare and Medicaid Services, the Joint Commission. Specification Manual for National Hospital Quality Measures, www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/ Current+NHQM+Manual.htm (accessed 2009 Feb 19).
21. Andes D, Anon J, Jacobs MR et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med. 2004; 24:477-502.
22. Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy. 2005; 25(10, pt. 2):55S-62S.
23. Rocephin (ceftriaxone sodium) prescribing information. Nutley, NJ: Roche Laboratories, Inc.; 2008 Aug. www.rocheusa.com/products/rocephin/pi.pdf.
24. Primaxin IV (imipenem and cilastatin for injection) prescribing information. Whitehouse Station, NJ: Merck & Co., Inc.; 2006 Jul.
25. Zosyn CP (piperacillin and tazobactam for injection) prescribing information. Philadelphia: Wyeth Pharmaceuticals Inc.; 2005 Jul.
26. Claforan (cefotaxime for injection, USP) prescribing information. Bridgewater, NJ: Sanofi-Aventis U.S. LCC; 2007 May.
27. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther. 2006; 4:479-90. (Pubitemid 43905469)
28. Vinks AA, Den Hollander JG, Overbeek SE et al. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother. 2003; 47:541-7.
29. Buck C, Bertram N, Ackermann T et al. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents. 2005; 25:62-7. (Pubitemid 40023348)
30. Munckhof WJ, Carney J, Neilson G et al. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 2005; 25:514-22. (Pubitemid 40732606)
31. Kasiakou SK, Sermaides GJ, Michalopoulos A et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005; 5:581-9. (Pubitemid 41196757)
32. Infectious Diseases Society of America. Penicillin's back: FDA raises breakpoints for S. pneumoniae pneumonia. www.idsociety.org/newsarticle.aspx?id= 11010 (accessed 2008 Aug 12).
33. Craig W. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA: 2002 Sep.
34. D'Ignazio J, Camere MA, Lewis DE et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother. 2005; 49:4035-41.
35. Drehobl MA, De Salvo MC, Lewis DE et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest. 2005; 128:2230-7. (Pubitemid 41507564)
36. Levaquin (levofloxacin) prescribing information. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2006 Jan.
37. Factive (gemifloxacin) prescribing information. Waltham, MA: Oscient Pharmaceuticals; 2004.
38. Avelox (moxifloxacin hydrochloride) prescribing information. West Haven, CT: Bayer Corporation; 2005 Jul.
39. Jones RN, Rubino CM, Bhavnani SM et al. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 2003; 47:292-6.
40. Ambrose PG, Grasela DM, Grasela TH et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793-7.
41. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125-9. (Pubitemid 28068302)
42. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003; 37:752-60. (Pubitemid 37153652)
43. Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007; 45:753-60.
44. Bartal C, Danon A, Schlaeffer F et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003; 114:194-8. (Pubitemid 36294004)
45. Owens RC Jr, Ambrose PG. Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. Diagn Microbiol Infect Dis. 2007; 57(3 suppl): 77S-83S.
46. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents. 2002; 19:349-53. (Pubitemid 34326395)
47. Rello J. Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. Eur Respir Rev. 2007; 16:33-9. (Pubitemid 47312073)
48. Bhavnani SM, Hammel JP, Cirincione BB et al. Use of pharmacokinetic- pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005; 49:3944-7.
49. Dandekar PK, Maglio D, Sutherland CA et al. Pharmacokinetics of mero-penem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003; 23:988-91. (Pubitemid 36903999)